These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21365672)

  • 1. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
    Yang C; Li Y
    Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hybrid design for dose-finding oncology clinical trials.
    Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
    Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
    Pan H; Zhu C; Zhang F; Yuan Y; Zhang S; Zhang W; Li C; Wang L; Xia J
    PLoS One; 2014; 9(5):e98147. PubMed ID: 24875783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A curve-free method for phase I clinical trials.
    Gasparini M; Eisele J
    Biometrics; 2000 Jun; 56(2):609-15. PubMed ID: 10877324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
    Ursino M; Biard L; Chevret S
    Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay of priors and skeletons in two-stage continual reassessment method.
    Iasonos A; O'Quigley J
    Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.
    Yan F; Mandrekar SJ; Yuan Y
    Clin Cancer Res; 2017 Aug; 23(15):3994-4003. PubMed ID: 28546227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid continuous reassessment method with overdose control for safer dose escalation.
    Ghosh D; Xie H; Zhang L; Chen F; Mohanty S; Li X
    J Biopharm Stat; 2023 Sep; 33(5):586-595. PubMed ID: 36715485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.